2 July, 2025
At BioGiv, we're proud to support early-stage biotech companies on their journey from lab to life-changing impact. One of our standout success stories from 2024 is Omnix Medical.
Here’s what they accomplished this past year:
-
Phase 2 Clinical Trial of OMN6
Omnix launched a Phase 2 clinical trial of its novel peptide OMN6 for severe hospital-acquired infections, with FDA approval and active sites in Israel, and plans to expand into Europe and Asia. -
Global Recognition
Omnix presented at leading international conferences:
• ID Week (Los Angeles) – Phase 1 trial results in healthy adults
• ESCMID Global (Barcelona) – Targeting A. baumannii, a high-priority resistant pathogen -
Clinical Partnership & Award-Winning Research
Together with Rabin Medical Center’s CF Clinic (led by Prof. Moshe Heching), Omnix demonstrated promising results for OMN51 in cystic fibrosis patients. The research earned the Outstanding Scientific Research Award at NACFC and NIACFC.
We're proud to support Omnix Medical as it pushes the boundaries of life-saving innovation.